Boston, Massachusetts 2021-06-16 07:00:35 –
THis week’s “First Opinion Podcast” is a special two-part episode focused on the controversial (and allegedly inflamed) FDA decisions. In these two episodes, we talk to two Alzheimer’s disease experts who have very different perspectives on news. And Jason Carrawish, a doctor with Alzheimer’s disease who doesn’t believe the drug is ready for approval.
Sercoe wrote his first opinion in 2019 on how aducanumab research can be done. “Open the floodgate” For other, perhaps better, treatments for Alzheimer’s disease. Carla Wish’s first opinion headline, published a week before the long-awaited FDA decision, briefly captures his position.If the FDA approves Biogen’s treatment for Alzheimer’s disease, I will not prescribe it.“
To find out more about Biogen news, go toRead loud.. “
Also, if you have feedback on the author of the first opinion featured in the podcast, the voice manifests, praises, darts, etc. that the host needs to litter. [email protected] Put “podcast” in the subject line.
Two Alzheimer’s experts with opposing viewpoints on Aduhelm Source link Two Alzheimer’s experts with opposing viewpoints on Aduhelm